Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, McIlleron H, De Azevedo V, Cox H, McDermid C, Sokhela S, Patel J, Meintjes G.

BMC Infect Dis. 2010 Mar 30;10:83. doi: 10.1186/1471-2334-10-83.

2.

Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses.

Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G.

PLoS One. 2009;4(2):e4520. doi: 10.1371/journal.pone.0004520.

4.

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

Fox MP, Sanne IM, Conradie F, Zeinecker J, Orrell C, Ive P, Rassool M, Dehlinger M, van der Horst C, McIntyre J, Wood R.

AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e.

5.

Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines.

Choun K, Pe R, Thai S, Lorent N, Lynen L, van Griensven J.

Bull World Health Organ. 2013 Mar 1;91(3):195-206. doi: 10.2471/BLT.12.111153.

6.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.

PMID:
20238364
7.

Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.

Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Makutu DK, Nfanyana K, Rantleru T, Tierney A, Nkakana K, Schwartz AB, Gross R, Macgregor RR, Bellamy SL, Frank I, Weissman D, Bisson GP.

J Infect Dis. 2013 Dec 1;208(11):1784-93. doi: 10.1093/infdis/jit368.

8.

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.

Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM.

PLoS Med. 2012;9(7):e1001270. doi: 10.1371/journal.pmed.1001270. Review.

9.

Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.

Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, Metcalf JA, Masur H, Hassim S.

AIDS. 2010 Jul 31;24(12):1849-55. doi: 10.1097/QAD.0b013e32833a2507.

10.

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE; CAMELIA (ANRS 1295–CIPRA KH001) Study Team..

N Engl J Med. 2011 Oct 20;365(16):1471-81. doi: 10.1056/NEJMoa1013911.

11.

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, Thawornwan U, Suntisuklappon B, Nilkamhang S, Sungkanuparph S; TIME Study Team..

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):377-83. doi: 10.1097/QAI.0b013e31825b5e06.

PMID:
22592586
12.
13.

Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa.

Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, De Azevedo V, Meintjes G.

PLoS One. 2011 May 12;6(5):e19484. doi: 10.1371/journal.pone.0019484.

14.

Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses.

Takuva S, Westreich D, Menezes CN, McNamara L, Sanne I, Page-Shipp L, Maskew M.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1358-64. doi: 10.5588/ijtld.11.0769.

15.

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221..

N Engl J Med. 2011 Oct 20;365(16):1482-91. doi: 10.1056/NEJMoa1013607.

16.

Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.

Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, Egger M, Africa FI.

PLoS One. 2013 Jun 5;8(6):e64392. doi: 10.1371/journal.pone.0064392.

17.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587.

18.

Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.

Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord..

Lancet HIV. 2016 Mar;3(3):e120-31. doi: 10.1016/S2352-3018(15)00252-0.

PMID:
26939735
19.

Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa.

Murphy RA, Sunpath H, Taha B, Kappagoda S, Maphasa KT, Kuritzkes DR, Smeaton L.

Int J Tuberc Lung Dis. 2010 Jul;14(7):903-8.

Items per page

Supplemental Content

Support Center